Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 0.1%

Bristol-Myers Squibb (NYSE:BMY)’s stock price was down 0.1% during mid-day trading on Wednesday . The company traded as low as $48.78 and last traded at $48.91. Approximately 838,596 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 15,723,794 shares. The stock had previously closed at $48.98.

Wall Street Analyst Weigh In

Several brokerages recently commented on BMY. Cantor Fitzgerald reiterated a “neutral” rating and set a $45.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen lifted their price target on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research report on Monday, August 12th. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $54.93.

Bristol-Myers Squibb Price Performance

The company has a current ratio of 1.16, a quick ratio of 0.99 and a debt-to-equity ratio of 2.86. The stock’s fifty day moving average price is $44.38 and its two-hundred day moving average price is $46.59. The firm has a market capitalization of $97.52 billion, a price-to-earnings ratio of -15.52, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. During the same period in the prior year, the firm posted $1.75 EPS. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 4.99%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Hedge Funds Weigh In On Bristol-Myers Squibb

Large investors have recently bought and sold shares of the stock. Northwest Financial Advisors purchased a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $27,000. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb during the first quarter worth approximately $27,000. LGT Financial Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the period. Pacific Capital Wealth Advisors Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $34,000. Finally, MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter worth $39,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.